Myopia prevention as a standard of care: The role of low-dose atropine

Prevention is a cornerstone of modern health care, and myopia should be no exception. As myopia prevalence rises worldwide, especially among children, the shift from reactive correction to proactive prevention is urgent. Optometry is positioned at the forefront of this evolving paradigm.

Historically, myopia was viewed as a simple refractive error managed with single-vision spectacles or contact lenses. Today, it is recognized as a progressive condition associated with sight-threatening complications, including retinal detachment, myopic maculopathy, glaucoma, and early cataract development. These risks highlight the importance of addressing not only visual acuity, but also myopia progression.¹

Optometrists are increasingly called upon to intervene early, especially when myopia develops in childhood. Early-onset myopia is more likely to progress to higher levels, increasing lifetime ocular risk. Slowing progression during childhood is essential to preserving eye health and reducing disease burden.^2,3

Low-dose atropine has emerged as a key tool in modern myopia management due to its demonstrated efficacy, favorable safety profile, and ease of clinical implementation. Supported by growing evidence, low-dose atropine offers optometrists a practical option for slowing pediatric myopia progression safely.⁴

Understanding myopia progression

Myopia, or nearsightedness, is a refractive condition in which distant objects appear blurred because light focuses in front of the retina instead of directly on it. Excessive axial elongation of the eyeball is the primary cause, although increased corneal or lens power may also contribute. Clinically, myopia is classified as low (−0.50 to −3.00 D), moderate (−3.00 to −6.00 D), or high (>−6.00 D). High myopia carries a significantly increased risk of sight-threatening complications, making early detection and intervention critical. The age of onset strongly influences progression; earlier-onset myopia tends to advance more rapidly, often resulting in higher final refractive errors.⁵

Axial elongation occurs naturally during childhood but is influenced by genetic and environmental factors. Children with 1 myopic parent are more likely to develop myopia, and risk increases substantially when both parents are affected. These children often experience earlier onset and faster progression.⁶

Environmental factors are major contributors to the rising prevalence of myopia. Prolonged near work, extended use of digital devices, intensive reading, and academic pressures have all been associated with accelerated progression. Conversely, increased outdoor time is protective. Exposure to natural light stimulates retinal dopamine release, which helps regulate axial growth and may reduce excessive elongation.^7-9

Myopia typically develops during early school years, coinciding with increasing near vision demands. Once present, it is irreversible and usually progresses through childhood and adolescence. Progression may slow during teenage years but can continue into adulthood in children with sustained near-work demands. Early-onset myopia is strongly linked to higher myopia later in life and greater risk of ocular complications.¹⁰

Without timely intervention, progressive myopia can advance rapidly, increasing the likelihood of lifelong vision-threatening issues. Optometrists are uniquely positioned to identify at-risk children, educate families, and implement evidence-based strategies to slow progression. By recognizing genetic and environmental risk factors, monitoring refractive changes and axial length, and promoting preventive measures such as outdoor activity, near vision habits counseling, and use of low-dose atropine when appropriate, clinicians can help safeguard long-term eye health. Early identification and proactive management allow optometrists to deliver the highest standard of pediatric vision care, reducing the burden of myopia on children, families, and public health.¹¹

Background on atropine in myopia management

Atropine has been used in myopia management for more than a century, with early observations linking its use to reduced myopia progression dating to the late 1800s. Initially, its effect was attributed to relaxation of accommodation, based on the belief that excessive near focusing was the primary driver of myopia. Although this theory guided early clinical practice, advances in vision science have revealed a more complex mechanism underlying atropine’s role in myopia control.¹²

Current evidence indicates that atropine acts primarily through retinal and scleral pathways rather than accommodation alone. It is thought to influence retinal dopamine modulation, altering biochemical signaling between the retina and sclera that regulates axial eye growth. By modifying these pathways, atropine helps limit excessive axial elongation, the structural hallmark of progressive myopia. This evolving understanding has directly influenced modern dosing strategies and renewed interest in low-dose formulations.¹³

Pivotal studies in the early 2000s demonstrated that very low concentrations of atropine, such as 0.01%, could significantly slow myopia progression with minimal effects on pupil size and accommodation. Recognizing that atropine’s efficacy is largely independent of its cycloplegic action paved the way for widespread clinical adoption.¹⁴ Today, low-dose atropine is used as part of myopia management, and FDA-approved formulation in the US is welcomed.

Low-dose atropine: Evidence and efficacy

Atropine 0.01% was the first low-dose concentration to gain widespread attention following landmark studies in the early 2000s. Its early popularity was driven by the ability to slow myopia progression with minimal adverse effects, making it highly acceptable to children and parents. As the science of myopia management evolved, however, it became clear that axial elongation, rather than refractive change alone, is the key structural driver of myopia progression and future ocular risk. Subsequent research demonstrated that atropine 0.01% has a relatively limited effect on axial length control, prompting investigation into higher low-dose concentrations.¹⁵

Concentrations such as 0.025% and 0.05% were explored to improve treatment efficacy while maintaining good tolerability. Among these, atropine 0.05% has emerged as the most effective low-dose option currently used in clinical practice. Multiple studies have shown a dose-dependent reduction in spherical equivalent progression and axial elongation with 0.05% atropine compared with lower concentrations. Importantly, these benefits are sustained over years of continuous treatment, supporting low-dose atropine as a long-term management strategy rather than a short-term intervention.¹⁶

Atropine 0.05% also demonstrates a favorable rebound profile compared with higher concentrations, which have historically been associated with accelerated progression after discontinuation. Taper schedule is recommended when discontinuing 0.05% atropine. In addition, low-dose atropine maintains a strong safety profile, with significantly fewer reports of photophobia, accommodative symptoms, or clinically significant pupil dilation. Long-term studies further confirm the absence of meaningful ocular or systemic adverse effects, supporting atropine 0.05% as a cornerstone therapy in evidence-based myopia management.¹⁷

Patient selection and clinical implementation of low-dose atropine

Successful myopia control relies heavily on patient adherence, making careful candidate selection critical. Ideal candidates are children with documented myopia progression of 0.50 D or more per year, axial elongation of 0.2 mm or more over a year, early-onset myopia, or a significant family history and premyopia. Treatment is typically initiated between ages 5 and 10 years following a thorough baseline examination, which should include cycloplegic refraction and, when available, axial length measurements. Because low-dose atropine is often obtained from compounding pharmacies, clinicians must pay careful attention to concentration, dosing instructions, and storage. Ongoing monitoring—both cycloplegic refraction and axial length measurements—every 6 months ensures treatment efficacy and supports adherence.¹⁸

Combination therapy and future directions

Combination therapy is an increasingly important strategy in modern myopia management. Low-dose atropine may be used alongside optical interventions such as orthokeratology and soft contact lenses with peripheral defocus to improve control of myopia progression, particularly in children at higher risk. For patients who continue to progress on a single modality, individualized treatment plans that consider age, rate of progression, axial length changes, and visual demands are essential to clinical decision-making. As research evolves, emerging pharmacologic options and optimized combination approaches are expected to further refine the future of myopia management.^19,20

Patient and parent counseling

Effective counseling is essential for successful myopia control. Families should receive clear instructions on proper dosing, frequency, administration technique, storage, and refill procedures when initiating low-dose atropine therapy. Setting realistic expectations is critical, as treatment is designed to slow, not stop, myopia progression. Mild, transient adverse effects such as photophobia or near blur may occur early and should be discussed proactively. Environmental strategies, including increased outdoor time and healthy near-work habits, play an important supportive role in treatment success. Direct, age-appropriate discussions with the child and parents reinforce that myopia management is a collaborative, long-term effort and help promote adherence and consistent follow-up.⁷

Conclusion

Early intervention is key to successful myopia management. Low-dose atropine offers a safe, practical, and evidence-based approach to slowing progression, and it can be combined with optical strategies when monotherapy proves insufficient. Although cost may be a factor, clinical trials and institutional programs often help provide access for families. Emerging research will continue to clarify the benefits of combination therapies, but current evidence supports early, proactive management as the standard of care. For clinicians, guiding children through myopia control not only protects long-term ocular health but also delivers the professional satisfaction of preventing avoidable vision complications. Myopia management is no longer a niche—it is now an integral part of pediatric eye care.

References

1. Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49. doi:10.1167/iovs.61.4.49

2. Hu Y, Ding X, Guo X, Chen Y, Zhang J, He M. Association of age at myopia onset with risk of high myopia in adulthood in a 12-year follow-up of a Chinese cohort. JAMA Ophthalmol. 2020;138(11):1129-1134. doi:10.1001/jamaophthalmol.2020.3451

3. Chua SY, Sabanayagam C, Cheung YB, et al. Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children. Ophthalmic Physiol Opt. 2016;36(4):388-394. doi:10.1111/opo.12305

4. Zadnik K, Schulman E, Flitcroft I, et al; CHAMP Trial Group Investigators. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023;141(10):990-999. doi:10.1001/jamaophthalmol.2023.2097

5. Flitcroft DI, He M, Jonas JB, et al. IMI - defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20-M30. doi:10.1167/iovs.18-25957

6. Jiang X, Tarczy-Hornoch K, Cotter SA, et al; POPEYE Consortium. Association of parental myopia with higher risk of myopia among multiethnic children before school age. JAMA Ophthalmol. 2020;138(5):501-509. doi:10.1001/jamaophthalmol.2020.0412

7. Martínez-Albert N, Bueno-Gimeno I, Gené-Sampedro A. Risk factors for myopia: a review. J Clin Med. 2023;12(18):6062. doi:10.3390/jcm12186062

8. Li X, Li L, Qin W, et al. Urban living environment and myopia in children. JAMA Netw Open. 2023;6(12):e2346999. doi:10.1001/jamanetworkopen.2023.46999

9. Ying ZQ, Li DL, Zheng XY, Zhang XF, Pan CW. Risk factors for myopia among children and adolescents: an umbrella review of published meta-analyses and systematic reviews. Br J Ophthalmol. 2024;108(2):167-174. doi:10.1136/bjo-2022-322773

10. Li T, Wei R, Du B, et al. Prevalence of myopia among children and adolescents aged 6–16 during COVID-19 pandemic: a large-scale cross-sectional study in Tianjin, China. Br J Ophthalmol. 2024;108(6):879-883. doi:10.1136/bjo-2023-323688

11. Lawrenson JG, Shah R, Huntjens B, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;2(2):CD014758. doi:10.1002/14651858.CD014758.pub2

12. Galvis V, Tello A, Parra MM, et al. Topical atropine in the control of myopia. Med Hypothesis Discov Innov Ophthalmol. 2016;5(3):78-88.

13. Sathyan S. Atropine in the treatment of childhood myopia. Kerala J Ophthalmol. 2019;31(1):4-10. doi:10.4103/kjo.kjo_6_19

14. Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347-354. doi:10.1016/j.ophtha.2011.07.031

15. Tan D, Tay SA, Loh KL, Chia A. Topical atropine in the control of myopia. Asia Pac J Ophthalmol (Phila). 2016;5(6):424-428. doi:10.1097/APO.0000000000000232

16. Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113-124. doi:10.1016/j.ophtha.2018.05.029

17. Hou P, Wu D, Nie Y, Wei H, Liu L, Yang G. Comparison of the efficacy and safety of different doses of atropine for myopic control in children: a meta-analysis. Front Pharmacol. 2023;14:1227787. doi:10.3389/fphar.2023.1227787

18. Lee SH, Tseng BY, Wang JH, Chiu CJ. Efficacy and safety of low-dose atropine on myopia prevention in premyopic children: systematic review and meta-analysis. J Clin Med. 2024;13(5):1506. doi:10.3390/jcm13051506

19. Yum HR, Han SY, Park SH, Shin SY. Synergistic effect of dual-focus soft contact lenses and 0.05% atropine on myopia control in children with rapidly progressing myopia. Eye Contact Lens. 2025;51(2):92-97. doi:10.1097/ICL.0000000000001154

20. Saw J. Combining forces: the latest on combination treatments in myopia management. Myopia Profile. February 17, 2025. Accessed February 23, 2026. https://www.myopiaprofile.com/articles/the-latest-on-combination-treatments-in-myopia-management